



ASX/MEDIA RELEASE

16 July 2018

Update on Scheme of Arrangement

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) (**Sirtex**) today announces that the US Federal Trade Commission has granted early termination of the waiting period under the Clayton Act and Premerger Notification Rules with respect to the Premerger Notification made by Sirtex and CDH Fund V, L.P. under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Receipt of this approval satisfies a condition to implementation of the scheme of arrangement proposed under the scheme implementation deed between Sirtex, CDH Genetech Limited and China Grand Pharmaceutical and Healthcare Holdings Limited (**Scheme**) and follows Sirtex's announcement on 3 July 2018 of receipt of Australian Foreign Investment Review Board clearance.

– ENDS –

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**
Visit us on LinkedIn: **Sirtex Medical Limited**

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406